Englewood Lab, Inc.

Englewood Lab, Inc.

KKRX:950140
6,040.00
KRW
+70.00
(+1.17%)
1,616.84EPS
5.29P/E
169.87BMarket Cap
Feb 19Next Earn
Englewood Lab, Inc.
KRX:950140
(Korea Stock Exchange)

Recent

price

6,040.00

P/E

ratio

5.29

div

yld

0.09%

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
5,491.46
6,418.79
4,470.44
5,979.74
6,875.82
6,809.76
8,095.87
7,548.94
10,407.78
9,116.63
10,938.02
10,908.93
Revenue per Share
509
-23
-712
-297
117
153
755
362
1,044
982
1,252
1,616.84
Basic EPS, GAAP
-225.17
-784.15
-987.28
-1,137.1
369.68
164.49
-470.36
265.85
907.85
424.03
789.74
1,486.54
Free Cash Flow per Basic Share
342.33
- -
- -
- -
- -
- -
- -
- -
- -
109.59
100.69
5.45
Dividend per Share
1,381.38
3,862.98
3,036.61
2,854.13
3,076.58
3,053.49
4,074.47
4,682.29
5,784.02
7,242.61
8,283.99
9,105.24
Book Value per Share
1,381.38
3,862.98
2,860.07
2,839.97
3,058.43
3,038.4
4,042.26
4,650.19
5,757.86
7,163.86
8,232.59
9,065.66
Tangible Book Value per Share
11
12
19
20
19
20
20
20
20
20
20
20
Basic Weighted Avg Shares
59,648
79,182
87,135
118,766
133,317
137,168
160,816
151,509
206,784
182,220
216,790
218,622
Sales/Revenue/Turnover
10.36
8.87
-10.18
-0.23
5.06
5.74
10.54
6.52
13.95
10.31
17.24
16.94
Operating Margin (%)
636
787
1,705
3,052
4,540
4,438
4,304
4,349
4,394
5,116
5,233
5,680
Depreciation Expense
5,529
-284
-13,878
-5,899
2,269
3,082
14,997
7,265
20,742
19,628
24,815
32,403
Net Income, GAAP
10.76
113.19
- -
- -
59.79
35.81
0.67
13.02
27.77
23.76
30.58
28.8
Effective Tax Rate (%)
9.27
-0.36
-15.93
-4.97
1.7
2.25
9.33
4.8
10.03
10.77
11.45
14.82
Profit Margin (%)
15,762
55,523
26,934
28,822
32,028
37,778
60,319
59,778
80,135
102,732
126,629
143,765
Working Capital
9,947
- -
11,778
16,055
14,397
15,866
17,355
6,520
4,191
7,620
6,063
5,540
LT Debt
26,752
74,811
60,331
56,705
61,125
60,666
80,951
93,027
114,916
143,895
164,585
180,902
Total Equity
- -
-1.64
- -
- -
3.07
5.72
17.55
7.64
16.79
9.35
14.1
14.28
Return on Invested Capital (%)
- -
-0.58
- -
- -
3.02
4.21
16.31
7.14
17.27
13.45
14.04
17.97
Return on Capital (%)
- -
-0.56
-20.54
-10.08
3.85
5.06
21.18
8.35
19.95
15.17
16.09
20.16
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
19,940
19,999
15,857
LT Borrowings
2,089
1,927
1,765
LT Finance Leases
3,974
3,911
3,774
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
223,712
235,434
169,870

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
176,257
184,272
186,394
Cash, Cash Equivalents & STI
48,823
57,525
59,210
Accounts Receivable, Net
82,699
84,439
82,993
Inventories
39,720
37,943
40,372
Total Current Liabilities
49,628
50,368
42,629
Payables & Accruals
- -
- -
- -
ST Debt
19,940
19,999
15,857
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.28%
22.3%
14.38%
Free Cash Flow
-4.31%
-53.88%
84.68%
Net Income, GAAP
506.77%
108.32%
26.42%
Sales/Revenue/Turnover
14.93%
11%
18.97%
Total Cash Common Dividend
- -
- -
-8.9%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
52,585
45,255
40,946
42,356
182,220
2025
42,531
58,466
63,057
54,524
216,790
2026
49,739
51,302
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
332
229
27
390.9
982
2025
160
143
565
375.55
1,252
2026
352
326
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
-5.2
11.28
109.59
2025
- -
- -
3.2
2.29
100.69
2026
- -
- -
- -
- -
- -
Business
Englewood Lab, Inc. is an original equipment manufacturer (OEM) and original design manufacturer (ODM) engaged in the research, development, formulation, and manufacturing of skincare, color cosmetics, and over-the-counter (OTC) personal care products. Founded in 2004 and headquartered in Totowa, New Jersey, the company operates as a key subsidiary of South Korea-based cosmetics manufacturer Cosmecca Korea Co., Ltd. Englewood Lab provides end-to-end turnkey beauty manufacturing solutions to global prestige cosmetic houses, masstige labels, dermatologist-backed skincare brands, and fast-growing indie beauty companies across North America, Asia, and Europe. The company operates through specialized business divisions covering skincare, hybrid makeup, and therapeutic personal care. Its comprehensive product portfolio includes anti-aging creams, serums, lotions, facial cleansers, hydrating toners, sheet masks, and chemical exfoliators; over-the-counter (OTC) therapeutic formulations, including broad-spectrum sunscreens, acne treatment solutions, skin-brightening preparations, and eczema-soothing barrier creams; hybrid color cosmetics and makeup products, including liquid foundations, tinted moisturizers, primers, BB and CC creams, concealers, lip treatments, and color-correcting emulsions; and specialty personal care items, including hydrating body washes, firming lotions, and scalp-care treatments. Englewood Lab provides an integrated suite of contract manufacturing services, encompassing custom formulation research and development; clinical and analytical stability testing; raw material procurement and quality assurance; regulatory compliance verification under United States Food and Drug Administration (FDA) cGMP guidelines; packaging design, compatibility testing, and sourcing; pilot batching; high-speed automated filling; secondary packaging assembly; and global logistics management. In recent developments, Englewood Lab has accelerated strategic initiatives to expand its production capacity, modernize manufacturing infrastructure, and capture surging demand from fast-growing indie beauty brands and clean cosmetics markets. The company has expanded its manufacturing capabilities across its primary facilities in Totowa, New Jersey, and its subsidiary, Englewood LAB Korea, based in Incheon, South Korea, integrating high-speed automated filling lines and upgrading OTC sunscreen manufacturing cleanrooms to meet stringent US FDA regulatory standards. The company has broadened its sustainable and clean beauty formulation platforms, launching new clean-certified, vegan, and microplastic-free cosmetic bases that comply with major global retailer clean beauty standards. Additionally, Englewood Lab has deepened its cross-border operational synergies with parent company Cosmecca Korea, deploying dual-track global supply chain solutions that enable international brand partners to formulate and manufacture locally in the United States while leveraging Korean cosmetic R&D and packaging technologies.